Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study

Table 2

Multivariate logistic regression analysis of factors associated with BCT.

	OR	95% CI	-value
Year			< 0.001
2000–2003 vs. 2008–2015	0.994	0.967–1.020	0.634
2004–2007 vs. 2008–2015	1.082	1.055–1.110	<0.001
Age, years			<0.001
64–72 vs. 18–63	1.306	1.273–1.340	<0.001
73–79 vs. 18–63	1.028	0.994–1.062	0.105
Race			< 0.001
Black vs. white	1.054	1.019–1.091	0.003
Others vs. white	0.747	0.722–0.772	<0.001
Histological type
IDC vs. ILC	1.367	1.317–1.418	<0.001
Grade			< 0.001
I vs. III/IV	1.486	1.438–1.536	<0.001
II vs. III/IV	1.137	1.109–1.166	<0.001
T stage			<0.001
T1a vs. T2	1.805	1.729–1.884	<0.001
T1b vs. T2	2.487	2.409–2.568	<0.001
T1c vs. T2	1.869	1.825–1.915	< 0.001
N stage			<0.001
N0 vs. N3	1.413	1.300–1.537	<0.001
N1 vs. N3	0.985	0.905–1.072	0.725
N2 vs. N3	1.109	1.007–1.223	0.036
ER
Negative vs. positive	0.874	0.843–0.906	<0.001
PR
Negative vs. positive	0.844	0.819–0.870	<0.001
Chemotherapy
No or unknown vs. Yes	0.701	0.684–0.719	<0.001

BCT, breast-conserving therapy; OR, odds ratio; CI, confidence interval; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor.